Announcements Trials
Browse Landscape

Phase

Phase NA 14Phase 2 11Phase EARLY_PHASE1 3Phase 1 3Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Positron Emission Tomography Computed Tomography × Clear all
NCT04552847 2022-02-17

Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

Universitaire Ziekenhuizen KU Leuven

Phase 2/3 Completed
85 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡